Voyager Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive (Loss)

**Consolidated Statements of Operations and Comprehensive (Loss)**Income

(amounts in thousands, except share and per share data)


· · Year ended ·
· · December 31,
· 2024 · 2023 · 2022
Collaboration revenue	$80,001	$250,008	$40,907
Operating expenses:
Research and development	127,368	92,172	60,764
General and administrative	35,920	35,822	30,980
Total operating expenses	163,288	127,994	91,744
Operating (loss) income	(83,287)	122,014	(50,837)
Other income, net:
Interest income	18,328	11,721	1,792
Other income	622	3	2,653
Total other income, net	18,950	11,724	4,445
(Loss) income before income taxes	(64,337)	133,738	(46,392)
Income tax provision	665	1,408	16
Net (loss) income	$(65,002)	$132,330	$(46,408)
Other comprehensive (loss) income
Net unrealized (loss) gain on available-for-sale-securities	(359)	171	(81)
Total other comprehensive (loss) income	(359)	171	(81)
Comprehensive (loss) income	$(65,361)	$132,501	$(46,489)

Net (loss) income per share, basic	$(1.13)	$3.08	$(1.21)
Net (loss) income per share, diluted	$(1.13)	$2.97	$(1.21)

Weighted-average common shares outstanding, basic	57,667,543	43,020,747	38,356,810
Weighted-average common shares outstanding, diluted	57,667,543	44,569,334	38,356,810

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.